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Abstract 
 
Background 
We have previously shown that the selective serotonergic re-uptake inhibitor, citalopram, reduces the neural 
response to reward and aversion in healthy volunteers. We suggest that this inhibitory effect might underlie 
the emotional blunting reported by patients on these medications. Bupropion is a dopaminergic and 
noradrenergic re-uptake inhibitor and has been suggested to have more therapeutic effects on reward-related 
deficits. However, how bupropion affects the neural responses to reward and aversion is unclear.  
 
Methods 
17 healthy volunteers (9 female, 8 male) received 7 days of bupropion (150 mg/day) and 7 days of placebo 
treatment, in a double-blind crossover design. Our functional Magnetic Resonance Imaging task consisted of 
3 phases; an anticipatory phase (pleasant or unpleasant cue), an effort phase (button presses to achieve a 
pleasant taste or to avoid an unpleasant taste) and a consummatory phase (pleasant or unpleasant tastes). 
Volunteers also rated wanting, pleasantness and intensity of the tastes. 
 
Results 
Relative to placebo, bupropion increased activity during the anticipation phase in the ventral medial 
prefrontal cortex (vmPFC) and caudate. During the effort phase, bupropion increased activity in the vmPFC, 
striatum, dorsal anterior cingulate cortex and primary motor cortex. Bupropion also increased medial 
orbitofrontal cortex, amygdala and ventral striatum activity during the consummatory phase.  
 
Conclusions 
Our results are the first to show that bupropion can increase neural responses during the anticipation, effort 
and consummation of rewarding and aversive stimuli. This supports the notion that bupropion might be 
beneficial for depressed patients with reward-related deficits and blunted affect.  
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Introduction 
 
Defined as the inability to experience pleasure from normally rewarding stimuli, anhedonia is one of 
the two main diagnostic criteria for depression.  Studies examining the effects of the current antidepressant 
treatments, selective serotonin reuptake inhibitors (SSRI), have found that the symptom of anhedonia is not 
effectively treated, which in turn predicts a longer time to recovery and fewer depression-free days (Shelton 
and Tomarken, 2001, Spijker et al., 2001). Further, there are reports that SSRIs can in fact contribute to 
emotional blunting in patients, where experiences, both positive and negative, are flattened (Price et al., 
2009). It has therefore been suggested that different pharmacological targets might be needed to adequately 
treat anhedonia and apathy in depression (Dunlop and Nemeroff, 2007, McCabe et al., 2009a, Nutt et al., 
2007) 
Anhedonia is multi-dimensional, with the anticipatory (appetitive/wanting) and consummatory 
(hedonic/liking) dimensions being the most widely examined in depression (Frey et al., 2015, McCabe, 
2014, Nutt et al., 2007). Affective neuroscience studies of reward ‘wanting’ and ‘liking’ have suggested that 
these psychological processes map onto distinct brain reward systems. For example, studies of pleasure 
identify hedonic impact in the ventral pallidum, nucleus accumbens and orbitofrontal cortex (OFC) (Berridge 
and Kringelbach, 2008, Peciña, 2008, Peciña and Berridge, 2005, Peciña et al., 2006, Smith and Berridge, 
2005, Wheeler and Carelli, 2006),  whereas “wanting” or incentive salience is mediated by neural systems 
that include mesolimbic dopamine projections from the ventral tegmental area to the ventral striatum 
(Berridge, 2007, Berridge et al., 2009). Further, dopamine has been shown to be involved in the learning 
about rewards in prefrontal cortical regions, such as the anterior cingulate cortex and the OFC (Dayan and 
Balleine, 2002).  
Examining the neural correlates of anhedonia in depression, studies have found reduced anticipatory 
and consummatory responses to reward in the ventral and dorsal striatum and the anterior cingulate (Epstein 
et al., 2006, Forbes et al., 2009, Pizzagalli et al., 2009a, Smoski et al., 2009, Ubl et al., 2015, Zhang et al., 
2013), with increased activity to the anticipation of gains in the anterior cingulate (Knutson et al., 2008). 
Unfortunately few studies investigate the separate dimensions of anhedonia within the same task, which may 
account for overlapping regions activated across studies in depression (Treadway and Zald, 2011, Zhang et 
al., 2013). Recent behavioural evidence suggests impairments in the amount of effort expended for rewards 
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in depressed patients (Sherdell et al., 2012, Treadway et al., 2012, Yang et al., 2014), suggesting another 
possible conceptual dimension of anhedonia needing further investigation. How effort expenditure might 
map onto neural processes in depression is as yet unclear. 
Studies examining the neural response to aversive stimuli in depression are less consistent, with 
some finding increased responses in regions such as the amygdala (Knutson and Greer, 2008, Sheline et al., 
2001, Surguladze et al., 2004), whilst others find reduced/blunted responses in the amygdala and lateral OFC 
(Bylsma et al., 2008, Luking et al., 2015, McCabe et al., 2009a). However, blunted responses to both reward 
and aversion fits with the theory of Emotion Context Insensitivity in depression, whereby patients exhibit 
reduced reactivity to all emotional stimuli (Rottenberg, 2007, Rottenberg et al., 2005).  
To assess the neural response to both reward and aversion, we have developed an experimental 
model that utilizes pleasant and unpleasant sights and tastes. We have previously shown that the SSRI, 
citalopram, reduced the neural response to the anticipation of reward in the ventral striatum, medial OFC and 
ventral medial prefrontal cortex (vmPFC) and in the ventral striatum to the taste of the reward 
(consummatory) (McCabe et al., 2010). Citalopram also reduced the neural activation to the anticipation of 
aversion in the insula and lateral OFC and to the aversive taste in the insula (consummatory) (McCabe et al., 
2010). We suggested that this general inhibitory effect might underlie the emotional dampening associated 
with SSRIs and their alleged inability to effectively treat reward-related deficits in depression (Kumar et al., 
2008, Opbroek et al., 2002, Price et al., 2009, Shelton and Tomarken, 2001). 
It has been suggested, however, that catecholamine antidepressants like bupropion (dopamine and 
noradrenaline reuptake inhibitor, DNRI) (Dwoskin et al., 2006, Stahl et al., 2004) might be more efficacious 
at improving reward-related deficits and apathy in depression and less likely to cause the negative side-
effects of sexual dysfunction seen with SSRIs (Argyropoulos and Nutt, 2013, M Pereira et al., 2014, Nutt et 
al., 2007, Shelton and Tomarken, 2001).  In fact a recent study examining the human response to erotic 
images found increased activity in the posterior midcingulate cortex, mediodorsal thalamus, and extended 
amygdala under bupropion (Abler et al., 2011). However, how the separate dimensions of neural reward and 
aversion processing (anticipation, effort and consummation) might be affected by bupropion is unknown and 
is therefore the aim of the current study. To do this we included in our task an anticipatory phase (pleasant or 
unpleasant cue), an effort phase (button presses to achieve a pleasant taste or to avoid an unpleasant taste) 
and a consummatory phase (pleasant or unpleasant tastes). We hypothesized that, unlike our previous results 
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with citalopram, bupropion would increase neural responses during anticipation in areas such as the striatum 
and anterior cingulate cortex. Further, we expected that during the effort phase bupropion would increase the 
neural activation in regions such as the striatum and prefrontal cortex, as these regions have recently been 
shown to be activated when working for rewards and avoiding aversion (Delgado et al., 2009, Wiers et al., 
2014). Additionally, we hypothesized that bupropion would increase neural responses in the striatum and 
medial OFC during the consummatory phase, given their involvement in hedonic processing. Finally, as with 
our previous work on the effects of 7 day treatments with antidepressants in healthy volunteers, we expected 
to find no observable behavioural effects on effort or subjective ratings for each of the stimuli (Harmer et al., 
2009, McCabe et al., 2010). 
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Materials and Methods 
 
Participants  
17 healthy right-handed and Caucasian volunteers (mean 24 years, nine female), were randomized to 
receive 7 days oral treatment with bupropion (150 mg/day) and 7 days oral treatment with placebo separated 
by a 2-week washout phase in a double-blind between-groups design. Our previous fMRI study indicated an 
effect size of d = 0.4 with a mean standard deviation of 0.25 (McCabe et al., 2009b), demonstrating that a 
sample size of 15 would be required to achieve 80% power at an alpha level of 5%. The study was located at 
the Centre for Neuroscience and Neurodynamics (CINN) in the Department of Psychology at the University 
of Reading. Volunteers were recruited via advertisement and, after reading study information, provided 
written consent prior to screening. Ethical approval was obtained from the University of Reading.  
The exclusion criteria included current/previous psychiatric disorder (including alcohol or drug 
dependency) using the DSM-IV Structured Clinical Interview [SCID (Spitzer et al., 2004)], pregnancy and 
any contraindications to MRI and bupropion (including family history of bipolar disorder and 
seizures/epilepsy).  Volunteers were medication-free for the past 3 months (excluding the contraceptive pill) 
before starting the study and underwent a physical examination. Volunteers had a healthy BMI and their 
liking and craving for chocolate was measured using a questionnaire (Rolls and McCabe, 2007). Eleven 
volunteers were non-smokers, four smoked < 1 cigarette a week, one smoked 5 cigarettes per week and one 
smoked 1-2 cigarettes a day on average. Baseline measures of mood and anhedonia were taken using the 
Beck Depression Inventory (Beck et al., 1961), Snaith-Hamilton Pleasure Scale (Snaith et al., 1995), 
Fawcett-Clarke Pleasure Capacity Scale (Fawcett et al., 1983), Temporal Experience of Positive Mood (Gard 
et al., 2007) and Behavioral Inhibition/Activation Scales (Carver and White, 1994). Given that we use taste 
stimuli, including chocolate, volunteers also completed the Eating Attitudes Questionnaire (Garner et al., 
1982) to assess eating attitudes. 
Experimental design 
The study used a double blind, within-subjects, counterbalanced, crossover design. Volunteers received 
7 days (1 tablet each morning) of bupropion treatment (150mg/day) and 7 days of placebo treatment, 
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separated by a 2-week washout phase. Treatment order was randomised, with 9 volunteers receiving 
bupropion first and 8 receiving placebo first. Volunteers underwent an fMRI scan on the 7th day of each 
treatment at approx. 3 hrs after last dose. One volunteer had a scan after 6 days treatment (drug) due to 
experiencing adverse side-effects. Medication was provided by the Oxford Health NHS Foundation Trust 
and the Royal Free London NHS Foundation Trust. Participants were asked to not consume chocolate for 24 
hours prior to scanning and were allowed only one caffeinated drink on the scan morning. Before scans, 
volunteers completed the Patient Rated Inventory of Side Effects (PRISE: Sequenced Treatment Alternatives 
to Relieve Depression) to record any adverse side-effects. Mood was measured before and after scans using 
the befindlichkeit scale of mood and energy (von Zerssen et al., 1974) and a mood visual analogue scale 
(VAS).  
 The task was adapted from (McCabe et al., 2010) to include an effort phase (Figure S1). The task 
(40 trials) had 4 conditions based on the trial type (reward/aversive) and its level of difficulty (easy/hard). 
Trial type was cued by a visual stimulus (chocolate picture or a picture of a mouldy drink, 2 sec, anticipatory 
phase), which indicated either to work to win the chocolate taste or to avoid the unpleasant taste. Difficulty 
was determined by the amount of effort required to complete the effort phase (easy = 24, hard = 45 button 
presses). The effort phase,  required volunteers to press a button as fast as possible (< 6 sec) to move a bar 
towards the pleasant chocolate picture (reward) and away from the unpleasant mouldy picture (aversive), 
allowing enough time to complete easy trials but not hard. A taste was then delivered (consummatory phase) 
based on performance. If on reward trials volunteers were successful they received the taste (5 sec delivery 
and 2 sec swallow cue) of chocolate and if not they received the tasteless solution. If on aversive trials 
volunteers were successful they received the tasteless solution and if not they received the unpleasant taste. 
A grey image (2 sec) followed by a tasteless rinse was presented at the end of each trial. Each condition was 
repeated 10 times, chosen by random permutation. Jitters were used for both interstimulus intervals and 
inter-trial intervals. To sustain effort, 4 trials (2 reward/2 aversive) were longer at 9 sec each. Volunteers also 
rated ‘wanting’, ‘pleasantness’ (+2 to –2) and ‘intensity’ (0 to +4) on a VAS on each trial (Figure S1).  
 
Stimuli 
We used a picture of liquid chocolate (reward), a mouldy drink (aversive) and a grey image 
(control). The rewarding taste was a Belgian chocolate drink and the aversive taste was a combination of the 
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chocolate drink mixed with beetroot juice, providing a similar texture. The tasteless solution (25 x 10-³mol/L 
KCL and 2.5x10-³mol/L NaHCO3 in distilled H2O) was also used as a rinse between trials. This was 
subtracted from the effects of the other taste stimuli to allow somatosensory and mouth movement effects to 
be removed (de Araujo et al., 2003, O'Doherty et al., 2001). Solutions were delivered through three teflon 
tubes held together by a plastic mouthpiece and connected by a one-way syringe-activated check valve 
(Model 14044-5, World Precision Instruments, Inc.), allowing 0.5 mL of solution to be manually delivered.  
 
 
fMRI Scan 
The experimental protocol consisted of an event-related interleaved design. A Siemens Magnetom 
Trio 3T whole body MRI scanner and a thirty-two-channel head coil were used. Multi-band accelerated 
pulse sequencing (Version number RO12 Center for Magnetic Resonance Research, University of 
Minnesota, EPI 2D BOLD/SE/DIFF Sequence) was used with an acceleration factor of 6. T2*-weighted 
echo planner imaging slices were obtained every 0.7 seconds (TR). Imaging parameters were chosen to 
reduce distortion artefact in the orbitofrontal cortex (Wilson et al., 2002). 54 Axial slices with in-plane 
resolution of 2.4 x 2.4mm and between plane spacing of 2.4mm were attained. The matrix size was 96 x 96 
and the field of view were 230 x 230mm. Acquisition was performed during task performance, yielding 
approximately 3500 volumes. An anatomical T1 volume with sagittal plane slice thickness 1mm and in-plane 
resolution of 1.0 × 1.0 mm was also acquired. 
 
fMRI analysis 
Statistical Parametric Mapping (SPM8: http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) was used 
to analyze the imaging data. The data was pre-processed using realignment, normalization to the Montreal 
Neurological Institute (MNI) coordinate system and spatial smoothing with a 6-mm full-width-at-half-
maximum Gaussian kernel and global scaling (Collins et al., 1994). The time series at each voxel was low-
pass filtered with a hemodynamic response kernel. Time series non-sphericity at each voxel was estimated 
and corrected for (Friston et al., 2002), and a high-pass filter with a cut-off period of 128 sec was applied.  
 In the single-event design, a general linear model was then applied to the time course of activation in 
which stimulus onsets were modelled as single impulse response functions and then convolved with the 
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canonical hemodynamic response function (Friston et al., 1994). Linear contrasts were defined to test 
specific effects. Time derivatives were included in the basis functions set. Following smoothness estimation 
(Worsley et al., 1996), linear contrasts of parameter estimates were defined to test the specific effects of each 
condition (pleasant/unpleasant cue – grey image and pleasant/unpleasant taste – rinse) with each individual 
dataset. Voxel values for each contrast resulted in a statistical parametric map of the corresponding t statistic, 
which was then transformed into the unit normal distribution (SPM z). Movement parameters for each person 
were added as additional regressors in the 1st level analyses.  
Second-level fMRI analyses first examined simple main effects of task with one-sample t-tests for 
all scans (Table S1). These results were thresholded at p=0.05 uncorrected and whole-brain cluster corrected 
[p<0.05 family-wise error (FWE) for multiple comparisons]. To examine the effect of bupropion, the one-
way ANOVA within-participants design implemented in SPM8 was used and all data were reported 
thresholded at p=0.05 uncorrected and whole-brain cluster corrected (p<0.05 FWE for multiple 
comparisons). Regions of interest, for which we had a priori hypotheses based our previous studies using a 
similar paradigm in healthy controls, were; ventral striatum [10, 12, -6; -6, 12, -4] (McCabe et al., 2010), 
caudate [-10, 12, 0; -10, 14, 0] (McCabe et al., 2010), medial OFC [2, 32, -24] (McCabe et al., 2010), 
vmPFC [8, 56, -12; 2, 44, -14] (McCabe et al., 2009b, McCabe et al., 2010) and lateral OFC [46, 34, -6] 
(McCabe et al., 2010). Peaks within 15mm of these locations and with a cluster threshold of at least 30 
contiguous voxels had small volume corrections for multiple comparisons applied (FWE, p<0.05). Plots of 
contrast estimates were extracted with plots tool in SPM8, and WFU Pick Atlas 
(http://www.fmri.wfubmc.edu/cms/software) was used to display neural activation, with error bars 
representing the standard error of the mean. Activation co-ordinates are listed in the stereotactic space of the 
MNI ICBM 152 brain (Table 2). 
 
Behavioral Data 
Data was analyzed using repeated measures ANOVA and employed the Bonferroni correction for 
multiple comparisons. Where sphericity was violated, the Greenhouse-Geisser correction was utilized. Not-
normally distributed data was transformed and reanalyzed. The reanalyzed data did not differ from raw data 
analysis and thus results are reported using the original data. Caution, however, might be paid to 
interpretation of the VAS analysis, because a proportion of the data was not normally distributed.  
  
 
10 
Dr Ciara McCabe.  
School of Psychology and Clinical Language Sciences, University of Reading, Reading RG6 6AL. 
 
Results 
Demographic Details and Mood Ratings 
Demographic data (Table 1) indicated that participants had low depression and anhedonia scores, as 
measured on range of mood and anhedonia questionnaires. Volunteers also scored low on the EAT and 
reported a strong liking of chocolate. A repeated-measures ANOVA was performed to examine the effect of 
treatment (bupropion/placebo) and time (pre/post scan) on mood and affect, as measured by the BFS and 
VAS (Table S2). Results revealed that there was no significant effect of treatment [F(1,16)=.483, p=.497], 
time [F(1,16)=.822, p=.378], treatment by time [F(1,16)=1.922, p=.185], treatment by VAS [F(1,16)=2.472, 
p=.084] or treatment by time by VAS interactions [F(1,16)=.689, p=.545]. There was also no significant 
effect of treatment [F(1,14)=1.61, p=.225] or treatment by time interaction [F(1,14)=2.176, p=.162] on total 
BFS scores. However, there was a significant main effect of time on overall BFS score [F(1,14)=5.879, 
p=.029]. 
  
 
11 
Dr Ciara McCabe.  
School of Psychology and Clinical Language Sciences, University of Reading, Reading RG6 6AL. 
 
 
Adverse effects 
Table S3 reports the number of adverse effects experienced on each treatment, as measured on the 
PRISE. The most commonly reported adverse effects across both treatment phases were headache (N= 5 per 
treatment), difficulty sleeping (N= 3 per treatment) and fatigue (N= 3 placebo, N= 5 bupropion). Dizziness 
(N= 4) was the most commonly reported adverse effect in the bupropion condition that was not reported in 
the placebo condition.  
 
Subjective Ratings of Stimuli 
Volunteers rated the chocolate cue and taste as pleasant and the unpleasant picture and taste as 
unpleasant (Figure S3). Using repeated-measures ANOVA with Ratings as the first factor with three levels 
(wanting, pleasantness and intensity), Treatment as the second factor with two levels (bupropion and 
placebo) and Condition as the third factor with two levels (rewarding and aversive), there was no significant 
main effect of treatment [F(1,16)=.867, p=.366] or treatment by condition interaction [F(1,16)=2.558, 
p=.129], treatment by rating interaction [F(1,16)=.109, p=.802] or treatment by rating by condition 
interaction [F(1,16)=.701, p=.479].  
 
Behavioral responses 
To examine whether there was an effect of treatment on the amount of effort invested into each 
condition (reward/aversion), repeated-measures ANOVAs were conducted on the average number of button 
presses made and the average amount of time it took to complete the effort stage (Figure S4). With 
Treatment (bupropion and placebo) and Condition (reward and aversion) included as factors, it was revealed 
that volunteers made significantly more button presses on aversive trials (M=37.69, SE = 0.33) compared to 
reward trials (M=37.37, SE=0.34) [F(1,16)=5.736, p=0.029]. This was independent of treatment, since there 
was no main effect of treatment [F(1,16)=.028, p=.869] or treatment by condition interaction [F(1,16)=.063, 
p=.804]. Furthermore, although volunteers completed aversive trials (M=5519.33ms, SE=46.43) quicker 
than reward trials (M=5546.57ms, SE=45.11), this was not significant [F(1,16)=2.106, p=.166], nor was 
there a main effect of treatment [F(1,16)=.023, p=.881] or treatment by condition interaction [F(1,16)=1.654, 
p=.217].  
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fMRI responses 
Table S1 in the Supplementary Material provides a summary of the results for each contrast across 
all volunteers to indicate the main effect of task. Table 2 provides a summary of the results of the interaction 
with Treatment.  
 
Table 2. Regions showing significant effect of treatment on each condition. 
 MNI coordinates   
Brain Region X Y Z Z score Significance 
(p Value) 
Anticipatory  
     Chocolate cue: bupropion > placebo      
          lOFC -42 44 -12 4.11 0.001* 
          Caudate -6 16 6 3.73 0.007* 
         pgACC/vmPFC 8 40 -8 3.33 0.02* 
     Unpleasant cue: bupropion > placebo      
         vmPFC -12 48 0 3.98 0.003* 
          Caudate  -4 16 6 3.61 0.01* 
Effort      
Easy chocolate – hard chocolate: 
bupropion > placebo 
     
          vmPFC 12 50 0 4.09 <0.001 
          Caudate 10 6 2 3.97 <0.001 
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          Putamen -14 8 0 3.45 <0.001 
          dACC/paracingulate gyrus -6 28 42 3.45 <0.001 
     Easy unpleasant – hard unpleasant:  
     bupropion > placebo 
     
          Ventral striatum/caudate -12 20 -6 3.42 <0.001 
      
          Primary motor cortex -38 -8 50 4.06 <0.001 
     Easy chocolate – easy unpleasant:  
     bupropion > placebo 
     
          Superior frontal gyrus -24 32 46 4.30 <0.001 
          dACC/paracingulate gyrus 6 28 42 4.10 <0.001 
Consummatory 
     Chocolate taste: bupropion > placebo      
          mOFC -2 28 -20 3.67 0.005* 
     Chocolate taste: placebo > bupropion      
          Caudate -2 8 10 4.07 <0.001 
     Unpleasant taste: bupropion > placebo      
          mOFC -2 28 -20 3.76 0.014  
          Amygdala 28 -2 -26 3.26 0.014  
          Ventral striatum  12 6 -6 3.11 0.014  
Data thresholded at p=0.05 uncorrected.  
p values, Family Wise Error Whole brain fully corrected or *Family Wise Error small volume 
correction p<0.05.  
pgACC, pregenual anterior cingulate cortex; vmPFC, ventromedial prefrontal cortex; dACC, dorsal anterior 
cingulate; mOFC, medial orbitofrontal cortex; Mid OFC, middle orbitofrontal cortex; lOFC, lateral 
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orbitofrontal cortex; Cing, cingulate 
Main Effect of Task 
As expected, the chocolate stimuli activated reward-related areas, such as the ventral striatum, the 
anterior cingulate and the OFC, whereas the unpleasant stimuli activated regions including the amygdala and 
lOFC. Both the chocolate taste and unpleasant tastes activated the insula (i.e. the primary taste cortex).  
 
 Anticipatory Phase 
 Relative to the placebo condition, the bupropion condition showed increased BOLD activity in the 
caudate in response to both the pleasant and unpleasant cue. To the pleasant cue, the bupropion condition 
showed more activity in the pgACC/vmPFC (Fig 1) and lOFC, in comparison to placebo. To the unpleasant 
cue, the bupropion condition showed more BOLD activity in the vmPFC, relative to placebo.   
 
Figure 1. Pleasant cue: left panel, axial, sagittal and coronal image of pgACC/vmPFC activation compared 
to placebo (Z=3.33, p=0.02 FWE svc for multiple comparisons); right panel, contrast estimates for paACC 
centered at 8, 40, -8. Error bars represent the standard error of the mean. 
 
 
Effort Phase 
For bupropion there was increased BOLD activity in the caudate, vmPFC (Figure 2), 
dACC/paracingulate gyrus and putamen for the easy chocolate trials compared to hard chocolate trials, in 
comparison to placebo. Bupropion also increased BOLD activity in the primary motor cortex and ventral 
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striatum/caudate for the easy unpleasant trials compared to hard unpleasant trials. Bupropion increased 
BOLD activity in the dorsal anterior cingulate cortex (dACC)/paracingulate gyrus and the superior frontal 
gyrus for the easy chocolate trials compared to the easy aversive trials, relative to placebo. 
 
 
Figure 2. Easy effort chocolate – hard effort chocolate: left panel, axial, sagittal and coronal image of 
vmPFC activation compared to placebo (Z=4.09, p<0.001 FWE whole brain cluster corrected for multiple 
comparisons); right panel, contrast estimates for vmPFC centered at 12, 50, 0. Error bars represent the 
standard error of the mean. 
 
 
Consummatory Phase 
Bupropion increased BOLD activity in the mOFC to both the pleasant (Figure 3) and unpleasant 
tastes. Bupropion increased BOLD activity in the amygdala (Figure 4) and ventral striatum for the 
unpleasant taste relative to the placebo condition. Bupropion also reduced BOLD activity for the pleasant 
taste in the caudate, relative to the placebo condition. 
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Figure 3. Chocolate taste: left panel, axial, sagittal and coronal image of mOFC activation compared to 
placebo (Z=3.67, p=0.005 FWE svc for multiple comparisons); right panel, contrast estimates for mOFC 
centered at 45, -2, 28. Error bars represent the standard error of the mean. 
 
Figure 4. Unpleasant taste: left panel, axial, sagittal and coronal image of amygdala activation compared to 
placebo (Z=3.26, p=0.014 FWE whole brain cluster corrected for multiple comparisons); right panel, 
contrast estimates for amygdala centered at 28,-2,-26. Error bars represent the standard error of the mean. 
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Discussion 
The aim of this study was to examine the effects of 7 days treatment with bupropion on the neural 
response to three phases of reward and aversion processing (anticipation, effort and consummation) in 
healthy volunteers. We found that bupropion increased neural responses during the anticipation, effort to 
achieve/avoid and the consummation of rewarding and aversive tastes. The effects on reward are consistent 
with the proposal that bupropion may significantly improve outcomes for depressed patients with 
predominant symptoms of decreased pleasure, interest and energy (Corcoran et al., 2004, Nutt et al., 2007). 
Further, bupropions ability to increase neural responses during anticipation, avoidance and consummation of 
aversive stimuli may be additionally beneficial for patients experiencing blunted affect in depression 
whereby reduced reactivity to positive and negative stimuli is predominant (Rottenberg, 2007, Rottenberg et 
al., 2005). 
Specifically we found that bupropion increased activity during the anticipation phase (pleasant and 
unpleasant cues) in the vmPFC and the caudate, with increased lateral OFC to the pleasant cue. These 
regions are recruited during anticipation of reward (Kim et al., 2010, Sescousse et al., 2013) and found 
blunted to the anticipation of reward in patients with depression (McCabe et al., 2009a, Price and Drevets, 
2009). We also found that the caudate was increased during the anticipation phase (pleasant and unpleasant 
cues) in the bupropion group compared to placebo. The caudate, which has been previously shown to be 
activated during the anticipation of pleasant and unpleasant stimuli in healthy volunteers (Knutson et al., 
2001; Greenberg et al., 2015) has been found hypoactive during the anticipation of reward in people with 
depression (Forbes et al., 2009, Smoski et al., 2009, Zhang et al., 2013). Thus bupropions ability to modulate 
activation in these regions during anticipation of reward and aversion might be a mechanism by which 
catecholaminergic medications are less likely to cause emotional blunting in depression compared to SSRI 
medications (Argyropoulos and Nutt, 2013, Bylsma et al., 2008, Nutt et al., 2007, Shelton and Tomarken, 
2001).  
During the effort phase, we found that there was more neural activity under hard trials than easy in 
the placebo group (Figure S2). We found that the activity under easy trials was potentiated by bupropion, in 
the striatum, vmPFC (Figure 2) and the dACC/motor areas, relative to placebo. Given the previous work 
showing that these regions are implicated in various processes involved in reward processing including 
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motor performance (Liljeholm and O’Doherty, 2012, Scholl et al., 2015) and in the avoidance of aversion 
(Kerr et al., 2012), its perhaps not surprising that bupropion enhanced this neural activity during effort 
expenditure to achieve reward and avoid aversion.  
During the consummatory phase we found that bupropion, compared to placebo, increased neural 
activity for both pleasant and unpleasant tastes in the mOFC. Our results are consistent with the literature 
indicating the involvement of the mOFC in hedonic experiences in humans and animals (Kringelbach, 2010, 
Peters and Buchel, 2010, Scott et al., 2005). Further, our previous study in those recovered from depression 
found reduced activity to the taste of chocolate (possible trait marker) in a similar subgenual/mOFC region to 
that enhanced by bupropion in this current study (McCabe et al., 2009a). Of note, a study by Pizaggalli et al. 
(2008) found reduced activations in depressed patients to both positive and negative outcomes in the striatum 
(Pizzagalli et al., 2009b) which is of interest given that we find enhanced striatal activation to the unpleasant 
taste under bupropion in our task. Taken together our results suggest that bupropion may be beneficial at 
increasing the neural deficits to both positive and negative consummatory stimuli in depressed patients who 
report blunted affect.  
As expected, there was no significant treatment effect on the amount of effort invested in the task or 
on the subjective reports of pleasantness, wanting and intensity for each of the stimuli. This is similar to our 
previous studies with acute pharmacological challenges in healthy volunteers and suggests that enhanced 
neural processing of reward/aversion after 7 days treatment does not necessarily become the subject of 
conscious awareness, although it could still presumably influence behavior (Horder et al., McCabe et al., 
2010, Tudge et al., 2015). Perhaps there is also a ceiling effect as volunteers are all healthy and do not have 
deficits in their ability to complete the effort component or to experience the tastes. However, how 
bupropion might affect these processes in studies with larger sample sizes and in depressed patients remains 
to be elucidated.  
To conclude, we suggest a potential mechanism of beneficial antidepressant drug action of 
bupropion that consists of enhancing the neural activation to reward and aversion during anticipation, effort 
and consummation. This profile of activity in turn could promote reward-seeking and aversive-avoidant 
behaviors in patients with depression, whereby a lack of drive to actively seek and experience rewards is 
coupled with a lack of drive to actively avoid negative experiences. Our results also support the notion that 
non-serotonergic antidepressants may play an important role specifically for patients that have a blunted 
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emotional affect and this fits with the Emotion Context Insensitivity theory of depression (Rottenberg et al., 
2005). Future research on the effects of bupropion on anticipation, effort and consummation of reward and 
aversion processing in depressed patients are encouraged to explore this notion further.  
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